Amira asset DP2 blockers spun out, not part of BMS $325 million buyout
This article was originally published in Scrip
Executive Summary
Just prior to Bristol-Myers Squibb wrapping up its buyout of San Diego-based Amira Pharmaceuticals, the company spun out certain assets that were not part of the deal into two separate companies.